CTI BioPharma

Seattle, United States Founded: 1991 • Age: 35 yrs Listed Acquired By Swedish Orphan Biovitrum
Targeted small molecule therapeutics for blood cancers are developed.

About CTI BioPharma

CTI BioPharma is a Healthcare company based in Seattle (United States) founded in 1991, and was acquired by Swedish Orphan Biovitrum in May 2023. Targeted small molecule therapeutics for blood cancers are developed. The company has 25 employees. CTI BioPharma has completed 1 acquisition, including Zhejiang Novus Pharmaceuticals. CTI BioPharma offers products and services including Haematology Treatments, Immunology Treatments, and Specialty Care Medicines. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is CTI BIOPHARMA CORP. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.

Company details

Developer of targeted small molecule therapeutics for blood cancer. Their flagship product Pixantrone was granted conditional marketing approval in the EU, as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. Other drugs in the pipeline are Pacritinib (myelofibrosis and relapsed acute myeloid leukemia), Tosedostat (relapsed acute myeloid leukemia and myelodysplastic syndrome), and Paclitaxel poliglumex (ovarian cancer).

Key Metrics

Products & Services of CTI BioPharma

CTI BioPharma offers a comprehensive portfolio of products and services, including Haematology Treatments, Immunology Treatments, and Specialty Care Medicines.

Haematology Treatments
Medical Treatments

Medicines for blood-related rare diseases

Immunology Treatments
Medical Treatments

Innovative therapies for rare immunological conditions

Specialty Care Medicines
Medical Treatments

Products for inflammation and genetic diseases

Funding Insights of CTI BioPharma

  • Total Rounds 7
  • Last Round Post-IPO β€” $45M
  • First Round $30M

    (Jan 2010)

  • Investors Count 2

All 7 funding rounds of CTI BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2017$45MPost-IPO––
Dec 2013$5MDebt – Venture––
Jan 2011$25MPost-IPO––
–
Aug 2010$4.6MPost-IPO––
–
Jun 2010$1.85MPost-IPO––
–
May 2010$21MPost-IPO––
–
Jan 2010$30MPost-IPO––
–
Valuation history

3 investors in total: 3 institutional.

Investors in CTI BioPharma

CTI BioPharma has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Swedish Orphan Biovitrum, Hercules Capital and Orbimed.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Venture debt financing is provided to companies in multiple sectors.
2003htgc.comPalo Alto, United States
Developer of therapies for rare diseases like Haemophilia, Inflammation, and Genetic diseases
1988sobi.comStockholm, Sweden
Premium access

Investor details for CTI BioPharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of CTI BioPharma

24 people are tracked at CTI BioPharma (9 in leadership, 4 in board & advisors, 11 in team); the tracked headcount is 25.

NameRoleGroup
Adam R. Craig
President, CEO & Interim Chief Medical OfficerLeadership
Derald Lo
Vice President Human ResourcesLeadership
Tom Blackwell
Vice President, Information TechnologyLeadership
Connie Providoshin
Regional Business DirectorLeadership
Joe Mansfield
VP US Sales And Sales OperationsLeadership
William Born
Senior Director Strategic Pricing And ContractingLeadership
Wendy Wilson
Associate Director Medical AffairsLeadership
Mary Beth Lanza
Senior Director Learning And DevelopmentLeadership
Allison Hylton
Senior Corporate Controller/senior DirectorLeadership
Michael A. Metzger
DirectorBoard & advisors
David Parkinson
DirectorBoard & advisors
Matthew D. Perry
DirectorBoard & advisors
Reed V. Tuckson
DirectorBoard & advisors
James K. Fong
SVP, Commercial OperationsTeam
Lisa Maggio
Sr Medical Science LiaisonTeam
Michael Spinek
Key Account ManagerTeam
Brent Satterlee
Senior Stock Plan ManagerTeam
Tina Bush
Key Account ManagerTeam
Bill Foxx
Key Account ManagerTeam
Joanna Thompson
Senior Medical Science LiaisonTeam

4 more people are available in the full profile.

Premium access

Complete people profiles for CTI BioPharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CTI BioPharma

CTI BioPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zhejiang Novus Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Generic drugs, APIs, and dietary supplements are developed and manufactured.
novuspharma.comShaoxing, China2015Jun 2003$192M
Premium access

Complete acquisition details for CTI BioPharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of CTI BioPharma

6 dated milestones of CTI BioPharma across 32 years, from founding to its latest funding, stage changes and deals.

  1. Founded CTI BioPharma is founded.
  2. Acquisition Acquires Zhejiang Novus Pharmaceuticals.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding First funding round of $30.0M.
  5. Funding Latest funding round, Post-IPO, of $45.0M.
  6. Exit Acquired by Swedish Orphan Biovitrum.

Competitors of CTI BioPharma

CTI BioPharma has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
bridgebio.com2015Palo Alto, United States$434.2M
Therapeutics for genetic diseases are developed through targeted interventions.
sparktx.com2013Philadelphia, United States$82.8M822
Gene therapies for rare diseases including retinal dystrophies are developed.
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
Premium access

Detailed competitors of CTI BioPharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of CTI BioPharma

Websites that share an audience with CTI BioPharma (ctibiopharma.com).

Similar websites

Websites whose visitors overlap most with CTI BioPharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
cytokinetics.com
100%
25.3K#1,072,700View details
curis.com
100%
4.8K#3,916,131View details
celsion.com
celsion.com
100%
#7,059,744–
celgene.com
100%
View details
wirb.com
61%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 6 similar websites and full traffic analytics for CTI BioPharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as CTI BioPharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cti Biopharma

Premium access

Complete news archive for CTI BioPharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CTI BioPharma

CTI BioPharma was founded in 1991 and raised its 1st funding round 19 years after it was founded.

CTI BioPharma is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

CTI BioPharma has 25 employees.

Developer of targeted small molecule therapeutics for blood cancer. Their flagship product Pixantrone was granted conditional marketing approval in the EU, as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. Other drugs in the pipeline are Pacritinib (myelofibrosis and relapsed acute myeloid leukemia), Tosedostat (relapsed acute myeloid leukemia and myelodysplastic syndrome), and Paclitaxel poliglumex (ovarian cancer).

CTI BioPharma's top competitors include Spark Therapeutics, BridgeBio and Alnylam.

CTI BioPharma offers Haematology Treatments, Immunology Treatments, and Specialty Care Medicines.

CTI BioPharma has made 1 acquisition, including Zhejiang Novus Pharmaceuticals.

CTI BioPharma has 3 investors. Key investors include Swedish Orphan Biovitrum, Hercules Capital, and Orbimed.

CTI BioPharma operates through Cti Biopharma Corp.

Yes. CTI BioPharma was acquired by Swedish Orphan Biovitrum in May 2023.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available